If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
183
results.
Updated on
07/11/2025 [06:52:00]
Results 150 to 175 of 183
Absstract of: WO2025217739A1
There is provided pharmaceutical compositions comprising disulfiram (DSF) or copper di-ethyldithiocarbamate (CuET), an indirubin compound such as 6-bromo-indirubin-3'-oxime (BIO), and a stabilizer, wherein the disulfiram or CuET, the indirubin compound, and the stabilizer are associated with a lipid nanoparticle. The pharmaceutical compositions are particularly suitable for treating a cancer overexpressing p97 and NPLOC4.
Absstract of: WO2025221606A1
The present disclosure relates to compounds of the various formulas disclosed herein, including Formula (I) and Formula (II), and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a compound of the various formulas disclosed herein, including Formula (I) and Formula (II), and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.
Absstract of: WO2025221397A1
The present disclosure provides a protein-based nanoparticle made of a protein and an amine for the delivery of a nucleic acid molecule, such as an mRNA vaccine, to a cell. The present disclosure further provides systems and methods for producing such protein-based nanoparticle including a nucleic acid molecule, and methods of delivering the nucleic acid molecule to a cell, and treating a subject with the compositions as disclosure herein.
Absstract of: WO2025217727A1
A conjugate compound comprises: TTA-X1-MNP-X2-TpA, wherein: TTA is a tumour targeting agent; MNP is a metal nanoparticle; TpA is a therapeutic agent; and X1 and X2 are the same or different, and are each independently selected from a non-covalent linker or a covalent linker. Methods for making the conjugate compound is provided. Methods and uses of the conjugate compound and a composition thereof for treating cancer.
Absstract of: WO2025217685A1
The present disclosure relates to quantum dot polymer compositions comprising a quantum dot, a polymer shell, optionally including a therapeutic agent and/or a target molecule, wherein the polymer shell comprises a first polymer layer comprising an endosomal disruptive polymer and a second polymer layer comprising a biopolymer suitable for oral administration. The present disclosure provides methods of making and using the compositions of the present disclosure.
Absstract of: US2025326810A1
Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNFα) and a cytokine selected from the group consisting of Interferon gamma (IFNγ) and Interleukin-12.
Absstract of: US2025326712A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations and pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.
Absstract of: US2025326708A1
The present disclosure relates to the field of medicine, specifically to a long-acting spleen-targeting cationic lipid compound comprising a benzene ring structure, a composition comprising the same, and a use thereof. More specifically, the present disclosure provides a compound of formula (I), or an N-oxide thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The present disclosure further provides a composition comprising the aforementioned compound and a use thereof in delivering therapeutic or prophylactic agents.
Absstract of: US2025325757A1
A cosmetic treatment method includes: applying, to skin or hair, an external preparation including a predetermined active ingredient and a base, and at least one of the active ingredient and the base contains fine water that is uncharged and has a particle size of less than or equal to 50 nanometers. Therefore, the applied fine water enters the skin or hair to contribute to maintenance of moisturization, and at the same time, forms a route through which the active ingredient permeates, thereby promoting the permeation of the active ingredient; therefore, the permeability of the active ingredient can be more appropriately improved.
Absstract of: US2025325702A1
Compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.
Absstract of: US2025325695A1
The present invention provides a method of a prophylaxis or a treatment of a pathological change of Bruch's membrane and/or an adjacent tissue, including a retinal pigment epithelium, a choroid, and an optic nerve head of an eye, e.g. a calcification of Bruch's membrane and/or the adjacent tissue, using a nanoparticle comprising a scaffold comprising a biodegradable material, an antibody targeted to a component of a Bruch's membrane, a component of a sub-retinal pigment epithelial deposit, or a component of an optic nerve head, and an anti-calcifying agent. Additionally, the present invention provides a pharmaceutical composition comprising said nanoparticle and one or more pharmaceutical acceptable excipient(s). Said pharmaceutical composition could be used in a method of prophylaxis or treatment of a pathological change of Bruch's membrane and/or adjacent tissues, including a retinal pigment epithelium and a choroid of an eye and/or a calcified sub-retinal pigment epithelium deposit and/or a calcified drusen.
Absstract of: US2025325699A1
The invention features polypeptides containing nuclear localization sequences that can be used to deliver polynucleotides to a cell. The polypeptides can be formulated with a polynucleotide and a lipid.
Absstract of: US2025325655A1
A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg/ml to 300 μg/ml; (2) Poly I:C: 400 μg/mL to 3000 μg/mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.
Absstract of: US2025325513A1
The present invention relates to a cabazitaxel prodrug anti-tumor preparation, designs and synthesizes a small molecule cabazitaxel prodrug with branched fatty alcohol involving formulas (I), (II) and (III) and containing different fatty alcohol side chains and different linking chains, and prepares a self-assembled nanoparticle. Results showed that the self-assembled nanoparticle of the small molecule cabazitaxel prodrug with branched fatty alcohol can effectively improve the efficacy of cabazitaxel, reduce toxic and side effects. The length of branched fatty alcohol side chains, the structure of the fatty alcohol side chains, the elemental composition of the linking chains and the length of the linking chains significantly affect preparation properties, in vivo fate and anti-tumor activity of the cabazitaxel-branched fatty alcohol prodrug self-assembled nanoparticle, which exhibits higher anti-tumor activity and lower toxicity compared with the self-assembled nanoparticle of small molecule cabazitaxel prodrug with straight-chain fatty alcohol.
Absstract of: US2025325491A1
The invention relates to nanoparticles particularly for nanoparticles suitable for the delivery of a nucleic acid to a cell. The nanoparticles comprise polyvalent molecules to stabilise the nucleic acid molecules in the nanoparticles. Particularly the polyvalent molecules have a dendrimer like structure. The invention further relates to manufacturing nanoparticles, and uses of such nanoparticles in the treatment of a disease.
Absstract of: US2025325493A1
Embodiments of the present disclosure provide novel compositions and methods for making and using polymer-coated nanocapsules. In certain embodiments, compositions and methods are disclosed for embedding at least one agent in a liquid fatty acid composition to form an inner core of the polymer-coated nanocapsule and coating the at least one agent-containing liquid fatty acid composition inner core with polymer to form at least one coating layer of polymer that further includes at least one positively charged surfactant (e.g., cationic surfactant), forming polymer-coated nanocapsules. In certain embodiments, the at least one positively charged surfactant binds to at least one targeting agent for directed use of the polymer-coated nanocapsules.
Absstract of: US2025325492A1
A composition including ionizable lipids is provided. Methods of making the ionizable lipids are also provided. Also provided are compositions forming lipid nanoparticles, wherein the composition includes the ionizable lipid, a helper lipid, a structural lipid or sterol, and a polymer-conjugated lipid. Methods of using the ionizable lipid and lipid nanoparticles are also provided.
Absstract of: US2025325490A1
The present disclosure provides a lipid compound, a lipid nanoparticle comprising the same and use thereof in the preparation of a drug delivery carrier. The lipid nanoparticle of the present disclosure can deliver a therapeutic or prophylactic agent (particularly a nucleic acid substance) to an injection site by intramuscular injection, and the therapeutic or prophylactic agent has high expression at the injection site but low expression in the viscera, which enables a drug to not only exert high activity but also have low visceral toxicity, and is of great significance to development and application of nucleic acid therapeutic or prophylactic agents.
Absstract of: US2025325593A1
The present invention provides an engineered mesenchymal stem cell (MSC), comprising: a mesenchymal stem cell; and at least one nanoparticle, retained in the MSC, wherein each nanoparticle comprises: a Fe-core and a shell coated on the Fe-core, and the shell has at least one of a hydroxyl group, a carbonyl group and an ether group. Besides, the present invention also provides a method for treating or preventing regenerative disease, comprising: administering an engineered mesenchymal stem cell to a subject in need thereof, wherein the engineered mesenchymal stem cell comprising: a mesenchymal stem cell (MSC); and at least one nanoparticle, retained in the MSC, wherein each nanoparticle comprises: a Fe-core and a shell coated on the Fe-core, and the shell has at least one of a hydroxyl group, a carbonyl group and an ether group.
Absstract of: US2025325495A1
Methods disclosed herein relate to generating silk nanoparticles with a low polydispersity index (PDI). Methods include adding a silk solution dropwise into a volatile solvent that is miscible with water, thereby forming a precipitate-bearing solution and applying shear forces to the precipitate-bearing solution for a length of time sufficient to achieve evaporation of at least 95% of the volatile solvent, thereby producing a population of silk fibroin nanoparticles in water having a polydispersity index (PDI) of 0.35 or less, including but not limited to, a PDI of 0.330 or less, 0.325 or less, 0.315 or less, 0.310 or less, 0.30 or less, 0.275 or less, 0.250 or less, 0.225 or less, or 0.200 or less. Parameters related to silk fibroin molecular weight, silk fibroin concentration, shear force application, and temperature may all be modified to achieve silk nanoparticles of a particular size exhibiting particular PDIs.
Absstract of: US2025325494A1
The present application provides a composition for organ-specific delivery of nucleic acids, which comprises a guided on-target lipid delivery lipid; further, the composition may comprise a helper lipid; still further, the composition may comprise a cationic lipid. The guided on-target lipid delivery lipid may be selected from one or more of an ionizable anionic steroid and/or an ionizable anionic polymer conjugated lipid; the helper lipid is optionally one or more of a phospholipid, a steroid, a polymer conjugated lipid, and a modifiable lipid; and the cationic lipid may be selected from one or more of a permanently cationic lipid and/or an ionizable cationic lipid. The delivery composition is capable of specifically delivering a prophylactic/therapeutic agent, particularly a nucleic acid component, to a target organ.
Absstract of: US2025325480A1
The invention provides novel compositions. methods and formulations employing lipid nanoparticle methods and systems for enhancing delivery and bioavailability of poorly soluble drugs, including cannabinoid drugs
Absstract of: AU2025200583A1
The present disclosure relates to the technical field of molecular biology and provides a lipid composition targeting antigen-presenting cells and a use thereof. The composition provided by the present disclosure demonstrates good organ and cell targeting specificity, significantly enhancing the protein expression level of antigens in the spleen. Additionally, the composition significantly increases the percentage of cells that express the antigen among antigen-presenting cells (e.g., B cells, pDC cells, cDC cells, and macrophages) in the spleen, indicating that the composition can be used in the immunotherapy of diseases. The present disclosure relates to the technical field of molecular biology and provides a lipid composition targeting antigen-presenting cells and a use thereof. The composition provided by the present disclosure demonstrates good organ and cell targeting specificity, significantly enhancing the protein expression level of antigens in the spleen. Additionally, the composition significantly increases the percentage of cells that express the antigen among antigen-presenting cells (e.g., B cells, pDC cells, cDC cells, and macrophages) in the spleen, indicating that the composition can be used in the immunotherapy of diseases. an h e p r e s e n t d i s c l o s u r e r e l a t e s t o t h e t e c h n i c a l f i e l d o f m o l e c u l a r b i o l o g y a n d p r o v i d e s a a n l i p i d c o m p o s i t i o n t a r g e t i n g a n t i g e n - p r e s e n t i
Absstract of: AU2024260092A1
The present disclosure in some aspects relates generally to nanoparticle compositions for oxygen delivery, method of use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to topical formulations capable of delivering oxygen to a tissue and methods of their use for treating diseases, such as hypoxemia.
Nº publicación: AU2024250062A1 23/10/2025
Applicant:
BEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO LTD
HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO LTD
BEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO., LTD,
HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO., LTD
Absstract of: AU2024250062A1
Provided herein are lipid nanoparticles comprising cationic steroid compound, as well as the preparation and uses of such lipid nanoparticles. Such lipid nanoparticles are useful in the delivery of payloads, such as nucleic acids, in vivo to non-hepatic organs (e.g., lung) for the treatment or prevention of certain diseases or disorders, particularly lung diseases.
BOPI
Electronic site
